#BEGIN_DRUGCARD DB00884

# AHFS_Codes:
92:00.00

# ATC_Codes:
M05BA07

# Absorption:
Rapid absorption (~1 hr) after an oral dose, occurs throughout the upper gastrointestinal tract

# Biotransformation:
No evidence found for metabolization of risedronate in humans or mammals

# Brand_Mixtures:
Actonal Plus Calcium (Warner Chilcott) (risedronate sodium hemi-pentahydrate + calcium carbonate)
Actonel with Calcium (Procter & Gamble) (risedronate sodium + calcium carbonate)

# Brand_Names:
Actonel
Actonel 150
Benet

# CAS_Registry_Number:
105462-24-6

# ChEBI_ID:
Not Available

# Chemical_Formula:
C7H11NO7P2

# Chemical_IUPAC_Name:
[1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2242518

# Description:
Risedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.

# Dosage_Forms:
Tablet, film coated	Oral
Tablet, film coated	Oral
Tablet, film coated	Oral
Tablet, film coated	Oral
Tablet, film coated	Oral

# Drug_Category:
Antihypocalcemic Agents
Antiresorptives
Bisphosphonates
Bone Density Conservation Agents
Calcium Channel Blockers

# Drug_Interactions:
Calcium	Formation of non-absorbable complexes
Calcium Acetate	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as risedronate. Avoid administration of oral calcium supplements within or 30 minutes after risedronate.
Calcium Chloride	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 30 minutes after alendronate/risedronate.
Iron Dextran	Formation of non-absorbable complexes
Magnesium	Formation of non-absorbable complexes

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-3.6

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Risedronate

# HET_ID:
RIS

# Half_Life:
1.5 hours

# InChI_Identifier:
InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)

# InChI_Key:
InChIKey=IIDJRNMFWXDHID-UHFFFAOYSA-N

# Indication:
For the treatment of Paget's disease of the bone (osteitis deformans), postmenopausal and glucocorticoid-induced osteoporosis

# KEGG_Compound_ID:
C08233

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
884

# Mechanism_Of_Action:
The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
283.1123

# Molecular_Weight_Mono:
283.001074735

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1RQJ
1YV5

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/act1580.shtml

# Pathways:
Risedronate Pathway	SMP00112

# PharmGKB_ID:
PA451255

# Pharmacology:
Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism and is indicated for the treatment and prevention of osteoporosis in postmenopausal women.

# Predicted_LogP_Hydrophobicity:
-0.75

# Predicted_LogS:
-1.4

# Predicted_Water_Solubility:
1.04e+01 g/l

# Primary_Accession_No:
DB00884

# Protein_Binding:
~24%

# PubChem_Compound_ID:
5245

# PubChem_Substance_ID:
46507526

# RxList_Link:
http://www.rxlist.com/cgi/generic/risedronate.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00410
DB02782

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
NE-58095
Risedronate sodium
Risedronic acid

# Synthesis_Reference:
Not Available

# Toxicity:
Side effects include abdominal pain, anxiety, back pain, belching, bladder irritation, bone disorders and pain, bronchitis, bursitis, cataracts, chest pain, colitis, constipation, depression, diarrhea, difficulty breathing, dizziness, dry eyes, eye infection, flu-like symptoms, gas, headache, high blood pressure, infection, insomnia, itching, joint disorders and pain, leg cramps, muscle pain, muscle weakness, nausea, neck pain, nerve pain, pain, pneumonia, rash, ringing in ears, sinus problems, sore throat, stomach bleeding, stuffy or runny nose, swelling, tendon problems, tumor, ulcers, urinary tract infection, vertigo, vision problems, and weakness.

# Update_Date:
2013-02-08 16:19:43 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Risedronate

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
PTGS2

# Phase_1_Metabolizing_Enzyme_1_ID:
290

# Phase_1_Metabolizing_Enzyme_1_Name:
Prostaglandin G/H synthase 2

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Prostaglandin G/H synthase 2 precursor
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
STEL

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P35354

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10620343	Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41.
11160603	Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
16006204	Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ: Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone. 2005 Sep;37(3):349-58.
16835450	Ortiz-Gomez A, Jimenez C, Estevez AM, Carrero-Lerida J, Ruiz-Perez LM, Gonzalez-Pacanowska D: Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate. Eukaryot Cell. 2006 Jul;5(7):1057-64.
18056045	Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007 Nov;1117:209-57.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
FDPS

# Drug_Target_1_GenBank_ID_Gene:
J05262

# Drug_Target_1_GenBank_ID_Protein:
182399

# Drug_Target_1_GeneCard_ID:
FDPS

# Drug_Target_1_Gene_Name:
FDPS

# Drug_Target_1_Gene_Sequence:
>1062 bp
ATGAACGGAGACCAGAATTCAGATGTTTATGCCCAAGAAAAGCAGGATTTCGTTCAGCAC
TTCTCCCAGATCGTTAGGGTGCTGACTGAGGATGAGATGGGGCACCCAGAGATAGGAGAT
GCTATTGCCCGGCTCAAGGAGGTCCTGGAGTACAATGCCATTGGAGGCAAGTATAACCGG
GGTTTGACGGTGGTAGTAGCATTCCGGGAGCTGGTGGAGCCAAGGAAACAGGATGCTGAT
AGTCTCCAGCGGGCCTGGACTGTGGGCTGGTGTGTGGAACTGCTGCAAGCTTTCTTCCTG
GTGGCAGATGACATCATGGATTCATCCCTTACCCGCCGGGGACAGACCTGCTGGTATCAG
AAGCCGGGCGTGGGTTTGGATGCCATCAATGATGCTAACCTCCTGGAAGCATGTATCTAC
CGCCTGCTGAAGCTCTATTGCCGGGAGCAGCCCTATTACCTGAACCTGATCGAGCTCTTC
CTGCAGAGTTCCTATCAGACTGAGATTGGGCAGACCCTGGACCTCCTCACAGCCCCCCAG
GGCAATGTGGATCTTGTCAGATTCACTGAAAAGAGGTACAAATCTATTGTCAAGTACAAG
ACAGCTTTCTACTCCTTCTACCTTCCTATAGCTGCAGCCATGTACATGGCAGGAATTGAT
GGCGAGAAGGAGCACGCCAATGCCAAGAAGATCCTGCTGGAGATGGGGGAGTTCTTTCAG
ATTCAGGATGATTACCTTGACCTCTTTGGGGACCCCAGTGTGACCGGCAAAATTGGCACT
GACATCCAGGACAACAAATGCAGCTGGCTGGTGGTTCAGTGTCTGCAACGGGCCACTCCA
GAACAGTACCAGATCCTGAAGGAAAATTACGGGCAGAAGGAGGCTGAGAAAGTGGCCCGG
GTGAAGGCGCTATATGAGGAGCTGGATCTGCCAGCAGTGTTCTTGCAATATGAGGAAGAC
AGTTACAGCCACATTATGGCTCTCATTGAACAGTACGCAGCACCCCTGCCCCCAGCCGTC
TTTCTGGGGCTTGCGCGCAAAATCTACAAGCGGAGAAAGTGA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
11773414	Lefebvre L, Vanderplasschen A, Ciminale V, Heremans H, Dangoisse O, Jauniaux JC, Toussaint JF, Zelnik V, Burny A, Kettmann R, Willems L: Oncoviral bovine leukemia virus G4 and human T-cell leukemia virus type 1 p13(II) accessory proteins interact with farnesyl pyrophosphate synthetase. J Virol. 2002 Feb;76(3):1400-14.
1968462	Wilkin DJ, Kutsunai SY, Edwards PA: Isolation and sequence of the human farnesyl pyrophosphate synthetase cDNA. Coordinate regulation of the mRNAs for farnesyl pyrophosphate synthetase, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and 3-hydroxy-3-methylglutaryl coenzyme A synthase by phorbol ester. J Biol Chem. 1990 Mar 15;265(8):4607-14.
2690933	Sheares BT, White SS, Molowa DT, Chan K, Ding VD, Kroon PA, Bostedor RG, Karkas JD: Cloning, analysis, and bacterial expression of human farnesyl pyrophosphate synthetase and its regulation in Hep G2 cells. Biochemistry. 1989 Oct 3;28(20):8129-35.
7584026	Nomura N, Miyajima N, Sazuka T, Tanaka A, Kawarabayasi Y, Sato S, Nagase T, Seki N, Ishikawa K, Tabata S: Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1. DNA Res. 1994;1(1):27-35.

# Drug_Target_1_HGNC_ID:
HGNC:3631

# Drug_Target_1_HPRD_ID:
00606

# Drug_Target_1_ID:
853

# Drug_Target_1_Locus:
1q22

# Drug_Target_1_Molecular_Weight:
40533

# Drug_Target_1_Name:
Farnesyl pyrophosphate synthetase

# Drug_Target_1_Number_of_Residues:
353

# Drug_Target_1_PDB_ID:
1YV5

# Drug_Target_1_Pathway:
Alendronate pathway	SMP00095
Atorvastatin Pathway	SMP00131
Cerivastatin Pathway	SMP00111
Fluvastatin Pathway	SMP00119
Ibandronate Pathway	SMP00079
Lovastatin Pathway	SMP00099
Pamidronate Pathway	SMP00117
Pravastatin Pathway	SMP00089
Risedronate Pathway	SMP00112
Rosuvastatin Pathway	SMP00092
Zoledronate Pathway	SMP00107

# Drug_Target_1_Pfam_Domain_Function:
PF00348	polyprenyl_synt

# Drug_Target_1_Protein_Sequence:
>Farnesyl pyrophosphate synthetase
MNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNR
GLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQ
KPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQ
GNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQ
IQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVAR
VKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK

# Drug_Target_1_Reaction:
dimethylallyl diphosphate + isopentenyl diphosphate = diphosphate + geranyl diphosphate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate

# Drug_Target_1_SwissProt_ID:
P14324

# Drug_Target_1_SwissProt_Name:
FPPS_HUMAN

# Drug_Target_1_Synonyms:
FPP synthetase
FPS
Farnesyl diphosphate synthetase

# Drug_Target_1_Theoretical_pI:
4.80

# Drug_Target_1_Transmembrane_Regions:
202-219; 322-344

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
16046206	Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20.
20209564	Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
Not Available

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Hydroxylapatite is the main mineral component of bone. Carbonated-calcium deficient hydroxyapatite is the main mineral of which dental enamel and dentin are comprised.

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
930

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
502.311

# Drug_Target_2_Name:
Hydroxyapatite

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
Not Available

# Drug_Target_2_SwissProt_Name:
Not Available

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB00884
